Defining oral treatment failure
In view of a patient that claims to have 'tried the tablet and achieved no result', several steps should be taken before classifying him as a 'nonresponder'.
Sildenafil: there are several reports showing that up to 56% of patients labeled 'nonresponders' to sildenafil, particularly the ones who are usually seen by nonspecialists, have actually not been using the drug properly; and that a high percentage of those patients-between 31 and 55%-move on to respond to sildenafil as they receive better instructions and are given the drug in an adequate manner. 1, 2 Before claiming a patient to be a nonresponder to sildenafil, the doctor should find out whether he meets the following requirements: that he has taken up to the maximal dose recommended: 100 mg; that he has taken the drug in at least four opportunities, with no satisfactory results; that his drug absorption has not had any gastric content interference: no eating, particularly of fatrich foods, 2 h before and 1 h after the drug administration; that he has waited at least 60 min between the drug ingestion and the intention to have the sexual intercourse; and that he has had adequate sexual stimulation.
In order to meet the recommendations made, followup visits ought to be scheduled to optimize the doctor-patient relationship and also for instructions with regard to the correct manner to administer the drug, defining its efficacy (expectations), adverse events and acceptance by the partner. Apomorphine: according to the manufacturer's data, although independent studies are not available yet, it is equally recommended that the adequate use of the pharmacological agent be instructed. The issues to be checked on in cases labeled as 'nonresponders to apomorphine' are: that he has achieved the maximal recommended dose: 3 mg; that he has taken the drug in at least four opportunities, with no satisfactory results; 3 that he has waited at least 20 min between ingestion of the drug and the intention to have the sexual intercourse; that he has not swallowed the tablet; and that he has had adequate sexual stimulation.
Drug switching and combination
Although there are no clinical trials to support such attitude, it is reasonable that, in view of a patient who has failed to respond to apomorphine, treatment with sildenafil, and vice versa, should be tried, provided there is no contraindication. There is no evidence under which to calculate the initial dose of sildenafil in patients who are nonresponders to apomorphine, and it is therefore recommended that conventional doses be followed.
Although the combination of a central action medication, such as apomorphine, with a different one of peripheral action, such as sildenafil, can be quite attractive, there are no clinical trials available yet to assess the safety and efficacy of those drugs when combined.
Therapeutic alternatives to oral treatment
Once it is confirmed that the patient is actually a nonresponder to oral treatment, different options should be proposed, according to the availability of drugs in the different countries and the patient's preferences and expectations.
Intraurethral therapy: alprostadil (MUSE s ) MUSE s ('Medicated Urethral System for Erection', Vivus, Inc.) was abandoned in Latin America, for its limited efficacy and its frequent adverse effects. Nevertheless, a recent study reports that about 30% of the 44 unsuccessful patients using sildenafil responded adequately by using MUSE. 4 
Topic therapy
Although well investigated in several clinical trials, topic or transdermal therapy is not commercially available in Latin America yet (by the time of this Consensus). There are no available data on its efficacy in patients in whom oral therapy failed.
Intracavernous therapy
Intracavernous pharmacotherapy continues to be the treatment of choice in cases of oral therapy failure. 5, 6 It is an alternative that has been used worldwide for almost 20 years.
The mostly used drugs, either alone or in combination, are: papaverine, phentolamine, alprostadil (PGE1), chlorpromazine, bimix (papaverine þ phentolamine or papaverine þ prostaglandin), and trimix (papaverine þ phentolamine þ prostaglandin or papaverine þ chlorpromazine þ prostaglandin).
The combined use makes the treatment safer, less expensive and more effective. These pharmacological agents availability varies a great deal from country to country, and it is frequently either the doctor himself or the pharmacist who make the proposed combinations.
The following care is recommended, as a rule, before starting intracavernous therapy:
(1) The patient should be told what the treatment involves, including its risks, characteristics and limitations, among further issues. (2) It is recommended to have his written consent.
(3) Much care should be taken in considering this type of treatment for patients with a history of hemorrhagic diatheses, hemoglobin disease, Peyronie's disease or prior history of priapism. The same care should be taken in regard to patients who find it difficult to understand the self-injection procedure, those showing important limitations in manual ability or visual acuity, the ones showing severe personality disorders, the extremely obese or the ones suspected of improperly using this type of drug. (4) Treatment should be started with the dose titration and instruction phase. In this period, increasing doses of the proposed intracavernous compound are administered, with results and adverse events assessed until the adequate dose for self-injection by the patient is defined.
(5) The patient should be instructed to visit his doctor immediately in case he should develop prolonged erection (between 2 and 4 h). (6) The patient should be periodically reviewed for his evolution to be controlled, to detect possible fibrosis areas and to have the doses adjusted to his needs. (7) In case the patient should have difficulties in understanding the use of the drug, the instructions can be given to his partner.
Priapism is one of the most frequent and feared complications. Its incidence is very small with the use of PGE1, higher with trimix and higher even with papaverine used alone. Pain is more usual when PGE1 is used. Bruising and ecchymosis, found in 2-10% of patients, are, as a rule, fewer and they recede without complications. Local fibrosis is a late complication that can vary from a small nodule in the tunica albuginea to largescale intracavernous fibrosis (rare).
The most common systemic complications are vasovagal events and syncope. More frequent liver complications have been reported with papaverine monotherapy.
Vacuum pumps
The vacuum pump is an alternative to achieve, through mechanical means, a state that is similar to erection. It is a plastic cylinder that, connected to a manual or mechanical vacuum pump, produces a negative pressure that fills up corpora cavernosa with blood. Once the erectile state is achieved, a constrictor ring is fitted over the base of the penis and it should be maintained until the peak of the sexual activity is achieved.
Its result is defined as a state similar to erection, since the tumescence achieved extends from the plastic ring to the distal part of the organ, causing, sometimes, the patient to complain about instability on the base of the penis, cyanotic aspect and low temperature (coldish). 7 It is a conservative alternative that some couples find attractive since it is noninvasive and requires no medication. It is a quite popular model in other countries, such as the United States, but of limited acceptance in Latin America.
It should be carefully used in patients on anticoagulants and with sensitivity alterations.
Psychosexual therapy
Some of the patients who failed in oral drug treatments have prevailing psychogenic factors that cannot be resolved with pharmacological therapy. An alternative is to combine or to introduce sexual therapy in the patients who have failed oral therapy and also that have clearly identified prevailing psychogenic factors.
It is reported in the literature that pharmacological treatment combined with sexual therapy helps prevent failures in the treatment. 8 The quality of the relationship with the partner is a further factor that, in certain occasions, may account for failure in oral therapy. Addressing those problems in the general urology practice, as well as referring a patient to a sexual therapist-as they are known-contributes to increase the possibilities for therapeutic efficacy. On the other hand, sexual therapy becomes more effective when combined with oral drug therapy.
